Literature DB >> 2265800

Serum-specific antibodies for Chlamydia trachomatis in preterm premature rupture of the membranes.

I Cohen1, E Tenenbaum, M Fejgin, G Michaeli, Y Beyth, I Sarov.   

Abstract

A case control study was performed to examine possible morbidity associated with Chlamydia trachomatis in 15 pregnant women with idiopathic preterm premature rupture of the membranes (PROM; group A), and in two control groups, 35 healthy preterm pregnant women (group B), and 43 healthy pregnant women at term (group C). Serum C. trachomatis IgG and IgA specific antibodies were determined using the single serovar (L2) inclusion immunoperoxidase assay. There were no significant differences in the prevalence rate of elevated levels of chlamydia IgG specific antibodies (titer greater than or equal to 1:128) between pregnant women suffering from idiopathic preterm PROM, as compared to healthy preterm and term pregnant women (20, 28 and 26%, respectively). Nor were there any significant differences in the prevalence rate of elevated levels of chlamydia IgA specific antibodies (titer greater than or equal to 1:16) between pregnant women with idiopathic preterm PROM, as compared to healthy preterm and term pregnant women (20, 20 and 17%, respectively). These findings do not support the assumption that C. trachomatis may play role in preterm PROM.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2265800     DOI: 10.1159/000293249

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  2 in total

Review 1.  Effect of Chlamydia trachomatis on adverse pregnancy outcomes: a meta-analysis.

Authors:  Weihua He; Yue Jin; Haibin Zhu; Yan Zheng; Jianhua Qian
Journal:  Arch Gynecol Obstet       Date:  2020-07-08       Impact factor: 2.344

2.  Chlamydia trachomatis and Adverse Pregnancy Outcomes: Meta-analysis of Patients With and Without Infection.

Authors:  Courtney Olson-Chen; Kripa Balaram; David N Hackney
Journal:  Matern Child Health J       Date:  2018-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.